aardvark - Search News

Aardvark, IPO and obesity

BioPharma Dive · 2d

Aardvark prices $94M IPO to fund Prader-Willi, obesity drug work

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, potentially, more common obesity-related conditions.

Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on the Nasdaq early Thursday.

Hosted on MSN · 3d

IPO Roundup: Karman Space & Defense, Aardvark Therapeutics and more

The U.S. IPO market is gaining momentum, with several issuers set for this week. Notably, defense contractor Karman Space & Defense (KRMN) aims to raise around $400M. "The company’s financials have shown growing topline revenue,

Benzinga.com · 3d

Preview: Aardvark Therapeutics, Inc Set To IPO Tomorrow

Aardvark Therapeutics, Inc AARD IPO will take place February, 13 on the NASDAQ exchange under the ticker AARD. The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on August 12, 2025.

Hosted on MSN1d

Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

FierceBiotech2d

Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Aardvark Lands $94M IPO as Biotech Wave Gains Momentum

Aardvark Therapeutics Inc. made its public market debut Thursday, securing $94 million in its initial public offering (IPO).

2d

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.

12d

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

FierceBiotech8d

CF-focused Sionna goes public in $135M IPO, while Aardvark plots $103M listing

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Aardvark stock sinks first day; IPO to fund obesity drugs

Raising $94.2 million in gross proceeds, Aardvark Therapeutics Inc. became the fifth biopharma company to list on Nasdaq so far in 2025.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results